Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3

J Prev Alzheimers Dis. 2018;5(3):184-187. doi: 10.14283/jpad.2018.22.

Abstract

Background: Clinical progression of Alzheimer's disease is characterized by impairment in cognition and function.

Objective: To assess the relationship between cognitive and functional impairment in mild Alzheimer's disease.

Design: Spearman's rank correlations between cognitive and functional measures were calculated. Autoregressive cross-lagged panel analyses were used to determine the temporal relationship between cognitive and functional decline.

Setting: Post-hoc analysis of clinical trial data.

Participants: Placebo-treated patients with mild Alzheimer's disease from the Phase 3 solanezumab study EXPEDITION 3.

Intervention: Placebo.

Measurements: Cognitive and functional measures were assessed at baseline and at six post-baseline time points through Week 80.

Results: Correlation between cognitive and functional measures was 0.41 at baseline and 0.65 at Week 80. Autoregressive cross-lagged panel analysis demonstrated that cognitive impairment preceded and predicted subsequent functional decline, but functional scores did not predict cognitive outcomes.

Conclusions: This study supports the hypothesis that functional impairment predictably follows cognitive decline in mild Alzheimer's disease dementia.

Keywords: Alzheimer’s disease; Cognition; correlation; function.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / complications
  • Alzheimer Disease / psychology*
  • Clinical Trials, Phase III as Topic / psychology*
  • Cognitive Dysfunction / complications
  • Cognitive Dysfunction / psychology*
  • Disease Progression
  • Humans
  • Neuropsychological Tests
  • Physical Functional Performance*
  • Placebo Effect